Investigating the Impact of Optimized Trans-Cinnamic Acid-Loaded PLGA Nanoparticles on Epithelial to Mesenchymal Transition in Breast Cancer

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Badawi N.M.; Attia Y.M.; El-Kersh D.M.; Hammam O.A.; Khalifa M.K.A.

Journal: International Journal of Nanomedicine

Publisher: Dove Medical Press Ltd

Publication Date: February 2022

Volume / Issue: Volume 17

Pages: 733–750

ISSN: 11769114

DOI: 10.2147/IJN.S345870

Scopus: View on Scopus

PubMed: 35210772

Document Type: Article

Access: All Open Access; Gold Open Access; Green Open Access


Authors and Affiliations

Badawi N.M., Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt; Attia Y.M., Department of Pharmacology, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt; El-Kersh D.M., Department of Pharmacognosy, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt; Hammam O.A., Department of Pathology, Theodor Bilharz Research Institute, Cairo, Egypt; Khalifa M.K.A., Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt


Abstract

Purpose: To design and optimize trans-cinnamic acid-loaded PLGA nanoparticles (CIN-PLGA-NPs) and assess its inhibitory effect on epithelial-mesenchymal transition (EMT) in triple-negative breast cancer. Methods: The quality by design approach was used to correlate the formulation parameters (PLGA amount and Poloxamer188 concentration) and critical quality attributes (entrapment efficiency percent, particle size and zeta potential). Design of CIN-PLGA-NPs formulations was done based on central composite response surface design and formulated by nanoprecipitation method. In addition, the optimized CIN-PLGA-NPs formulation was further evaluated for morphology using transmission electron microscopy and in vitro dissolution test. The cytotoxicity of CIN-PLGA-NPs optimized formula in comparison to the free trans-cinnamic acid (CIN-Free) was investigated in vitro using MDA-MB-231, triple-negative breast cancer cells, followed by scratch wound assay for evaluating the impact on the migratory potential of MDA-MB-231 cells. In vivo antitumor activity was evaluated using Ehrlich ascites carcinoma solid tumor animal model where tumor volumes were measured at different time points and necrotic/apoptotic indices were estimated in tumor sections. EMT markers, E-and N-cadherin, were assessed in solid tumors as well. Results: The optimized formulation showed entrapment efficiency of 76.98%, particle size of 186.3 nm with a smooth spherical surface and zeta potential of −28.47 mV indicating its stability. Furthermore, CIN-PLGA-NPs optimized formula released 60.8±1.89% of the total CIN-Free within 24 hours compared to 29±1.25% of the raw CIN-Free indicating improved dissolution rate. The optimized formula showed superior cytotoxicity on MDA-MB-231 cells compared to its free counterpart as well as increased wound closure percentage along with reduced tumor size in mice and increased necrotic and apoptotic indices. Tumor levels of E-cadherin and N-cadherin were indicative of EMT inhibition. Conclusion: Our findings proved the capability of PLGA nanoparticles in loading trans-cinnamic acid in addition to enhancing its antitumor efficacy in triple-negative breast cancer possibly via inhibiting EMT. © 2022 Badawi et al.


Keywords

Breast cancer; Epithelial-mesenchymal transition; PLGA nanoparticles; Quality by design; Trans-cinnamic acid; Animals; Breast Neoplasms; Cinnamates; Drug Carriers; Female; Humans; Mice; Nanoparticles; Particle Size; caspase 3; cinnamic acid; nanoparticle; nerve cell adhesion molecule; polyglactin; uvomorulin; drug carrier; animal experiment; animal model; animal tissue; apoptosis; Article; cell migration; controlled study; cytotoxicity; drug delivery system; drug solubility; Ehrlich ascites tumor; immunoreactivity; in vitro study; MDA-MB-231 cell line; mouse; nanopharmaceutics; nonhuman; solid malignant neoplasm; surface property; transmission electron microscopy; triple negative breast cancer; tumor volume; zeta potential; animal; breast tumor; epithelial mesenchymal transition; human


Citation Information

Scopus Citations: 27


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer